Skip to main content
PMC home page
Neuropsychopharmacology logoLink to Neuropsychopharmacology
. 2022 Jun 14;47(9):1733. doi: 10.1038/s41386-022-01345-x

Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model

Christina Gross 1,2,✉, Anwesha Banerjee 3, Durgesh Tiwari 1, Francesco Longo 4, Angela R White 1, A G Allen 5,6, Lindsay M Schroeder-Carter 1, Joseph C Krzeski 1, Nada A Elsayed 1, Rosemary Puckett 4, Eric Klann 4, Ralph A Rivero 7, Shannon L Gourley 5,6,8,✉, Gary J Bassell 3,9,✉
PMCID: PMC9283376  PMID: 35701551

Correction to: Neuropsychopharmacology 10.1038/s41386-018-0150-5, published online 13 July 2018

In this article, Dr. Gary J. Bassell (gary.bassell@emory.edu) has been added as corresponding author in the web version of this article. The original article has been corrected.

Contributor Information

Christina Gross, Email: christina.gross@cchmc.org.

Shannon L. Gourley, Email: shannon.l.gourley@emory.edu

Gary J. Bassell, Email: gary.bassell@emory.edu

Articles from Neuropsychopharmacology are provided here courtesy of Nature Publishing Group

RESOURCES